Eversept Partners LP Invests $1.80 Million in Inovio Pharmaceuticals, Inc. $INO

Eversept Partners LP acquired a new stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the first quarter, HoldingsChannel.com reports. The fund acquired 1,035,360 shares of the biopharmaceutical company’s stock, valued at approximately $1,802,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the period. Focus Partners Wealth bought a new stake in Inovio Pharmaceuticals during the third quarter valued at about $33,000. Raymond James Financial Inc. grew its holdings in Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares during the period. GSA Capital Partners LLP increased its position in Inovio Pharmaceuticals by 3.8% in the fourth quarter. GSA Capital Partners LLP now owns 459,828 shares of the biopharmaceutical company’s stock worth $800,000 after buying an additional 16,724 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Inovio Pharmaceuticals in the third quarter worth about $41,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. HC Wainwright reduced their target price on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, June 1st. Finally, Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 1st. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.25.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $0.97 on Tuesday. Inovio Pharmaceuticals, Inc. has a fifty-two week low of $0.96 and a fifty-two week high of $2.98. The company has a market capitalization of $79.40 million, a P/E ratio of -0.67 and a beta of 1.48. The company has a fifty day moving average of $1.15 and a 200 day moving average of $1.37.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Analysts forecast that Inovio Pharmaceuticals, Inc. will post -1.03 EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.